09.27.13
The first Extreme Lateral Interbody Fusion (XLIF) procedures, developed by San Diego, Calif.-based NuVasive Inc., have been performed in Japan in two different hospitals.
The XLIF technique is a minimally disruptive surgical procedure performed through the side of the body. It is designed to treat a range of spinal pathologies. The procedure reportedly enables the surgeon to gain lateral access to the spinal column, avoiding any major nerves in the area between the incision and the column using nerve monitoring technology. The XLIF procedure does not require an anterior or posterior exposure, and thereby eliminating the traditional risks of those procedures, including vascular and neural injury.
NuVasive has received regulatory Shonin approval from Japan’s Pharmaceuticals Medical Devices Agency for several products to be used in the XLIF surgical technique as a minimally invasive option for lumbar spine fusion. This approval adds the XLIF approach to the cervical and posterior products that were approved for use late last year.
“We are absolutely thrilled that NuVasive now offers our comprehensive portfolio of innovative, procedurally integrated solutions for spine surgery in Japan, including XLIF,” said Russell Powers, NuVasive executive vice president of international business. “The XLIF procedure changed spine surgery in the United States with a minimally invasive approach designed to achieve reproducible, superior patient outcomes. We are eager to introduce XLIF across Japan, and to drive the shift toward minimally invasive approaches in the world’s second largest spine market. Our initial reception in Japan has been fantastic, and I applaud all of the NuVasive teams who worked to establish our Absolutely Responsive direct operation in this exciting new market.”
NuVasive makes minimally disruptive surgical products and procedures for the spine.
The XLIF technique is a minimally disruptive surgical procedure performed through the side of the body. It is designed to treat a range of spinal pathologies. The procedure reportedly enables the surgeon to gain lateral access to the spinal column, avoiding any major nerves in the area between the incision and the column using nerve monitoring technology. The XLIF procedure does not require an anterior or posterior exposure, and thereby eliminating the traditional risks of those procedures, including vascular and neural injury.
NuVasive has received regulatory Shonin approval from Japan’s Pharmaceuticals Medical Devices Agency for several products to be used in the XLIF surgical technique as a minimally invasive option for lumbar spine fusion. This approval adds the XLIF approach to the cervical and posterior products that were approved for use late last year.
“We are absolutely thrilled that NuVasive now offers our comprehensive portfolio of innovative, procedurally integrated solutions for spine surgery in Japan, including XLIF,” said Russell Powers, NuVasive executive vice president of international business. “The XLIF procedure changed spine surgery in the United States with a minimally invasive approach designed to achieve reproducible, superior patient outcomes. We are eager to introduce XLIF across Japan, and to drive the shift toward minimally invasive approaches in the world’s second largest spine market. Our initial reception in Japan has been fantastic, and I applaud all of the NuVasive teams who worked to establish our Absolutely Responsive direct operation in this exciting new market.”
NuVasive makes minimally disruptive surgical products and procedures for the spine.